Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

Abstract Background Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes, resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall survival. Whilst Sorafenib and Lenvatinib are now licenced for the treatmen...

Full description

Bibliographic Details
Main Authors: Sarah R. Brown, Andrew Hall, Hannah L. Buckley, Louise Flanagan, David Gonzalez de Castro, Kate Farnell, Laura Moss, Rebecca Gregory, Kate Newbold, Yong Du, Glenn Flux, Jonathan Wadsley
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Cancer
Subjects:
Iodine refractory differentiated thyroid cancer
MEK inhibitor
Selumetinib
Radioiodoine therapy
Phase II
Dosimetry
Online Access:http://link.springer.com/article/10.1186/s12885-019-5541-4

Internet

http://link.springer.com/article/10.1186/s12885-019-5541-4

Similar Items